Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib after checkpoint inhibitor therapy in advanced/metastatic renal cell carcinoma
2017-000708-10Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC) and Nephroma, sponsored by Novartis. Primary endpoint: Progression-free survival. Started Jul 2017; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)Nephroma
Beyond the preview
Go deeper on 2017-000708-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000708-10.